共 163 条
[1]
Armstrong GL(2006)The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 705-714
[2]
Wasley A(2002)The burden of hepatitis C in the United States Hepatology 36 S30-S34
[3]
Simard EP(2009)Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 1335-1374
[4]
McQuillan GM(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958-965
[5]
Kuhnert WL(2004)Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-355
[6]
Alter MJ(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982
[7]
Kim WR(2003)Pharmacokinetics of peginterferons Semin Liver Dis 23 23-28
[8]
Ghany MG(1996)Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1-12
[9]
Strader DB(2010)Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C Gastroenterology 138 108-115
[10]
Thomas DL(2009)Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580-593